Formycon AG (ETR:FYB)

Market Cap	418.47M
Revenue (ttm)	69.67M
Net Income (ttm)	-125.67M
Shares Out	17.66M
EPS (ttm)	-7.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,573
Average Volume	25,709
Open	23.30
Previous Close	22.95
Day's Range	23.10 - 24.20
52-Week Range	19.18 - 64.40
Beta	0.58
RSI	53.33
Earnings Date	May 15, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 250
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: FYB